Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia

N. P. Kirsanova; Кирсанова Н. П.; O. V. Aleinikova; Алейникова О. В.; A. M. Kustanovich; Кустанович А. М.; T. V. Savitskay; Савицкая Т. В.; R. I. Yutskevich; Юцкевич Р. И.; E. V. Volochnik; Волочник Е. В.; L. V. Baidun; Байдун Л. В.; Yu. E. Mareiko; Марейко Ю. Е.; Yu. S. Strongin; Стронгин Ю. С.; N. V. Minakovskay; Минаковская Н. В.; N. V. Migal; Мигаль Н. В.; I. V. Proleskovskay; Пролесковская И. В.; I. V. Emelyanova; Емельянова И. В.; O. V. Karas; Карась О. В.; A. G. Drekov; Дреков А. Г.; M. M. Maschan; Масчан М. М.; D. V. Litvinov; Литвинов Д. В.; N. V. Myakova; Мякова Н. В.; E. V. Skorobogatova; Скоробогатова Е. В.; D. D. Baidildina; Байдильдина Д. Д.; I. I. Kalinina; Калинина И. И.; G. G. Solopova; Солопова Г. Г.; E. V. Suntsova; Сунцова Е. В.; U. N. Petrova; Петрова У. Н.; L. A. Hachatryan; Хачатрян Л. А.; M. M. Scheider; Шнейдер М. М.; A. A. Maschan; Масчан А. А.

doi:10.17650/1818-8346-2009-0-1-5-13

Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia

Authors: Kirsanova N.P.¹, Aleinikova O.V.¹, Kustanovich A.M.¹, Savitskay T.V.¹, Yutskevich R.I.¹, Volochnik E.V.¹, Baidun L.V.², Mareiko Y.E.¹, Strongin Y.S.¹, Minakovskay N.V.¹, Migal N.V.¹, Proleskovskay I.V.¹, Emelyanova I.V.¹, Karas O.V.¹, Drekov A.G.¹, Maschan M.M.³^,2, Litvinov D.V.³^,2, Myakova N.V.³^,2, Skorobogatova E.V.³^,2, Baidildina D.D.², Kalinina I.I.², Solopova G.G.², Suntsova E.V.², Petrova U.N.², Hachatryan L.A.², Scheider M.M.³, Maschan A.A.³
Affiliations:
1. Republic Centre for Paediatric Oncology and Haematology
2. Russian Children Clinical Hospital
3. Federal Research Center of Pediatric Hematology, Oncology and Immunology
Issue: No 1 (2009)
Pages: 5-13
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CARE
Published: 24.02.2009
URL: https://oncohematology.abvpress.ru/ongm/article/view/645
DOI: https://doi.org/10.17650/1818-8346-2009-0-1-5-13
ID: 645

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are included in the study. In 91 patients (86.7%) hematological remission have reached, from them 34 patients (37.4%) are in the first continuous complete remission (CCR). 6-years overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) rate for all group of patients was 0.35 ±} 0.05; 0.32 ±} 0.04 and 0.43 ±} 0.05, respectively. Survival analysis of children with different cytogenetic anomalies has allowed to define two prognostic groups of patients: the intermediate prognosis, including patients with normal kariotype and t(9;11) which EFS and RFS rate was 40—50%, and unfavorable prognosis with EFS and RFS rate less than 40%. The efficiency analysis of three postremission therapy type (allogeneic and autological hematopoietic stem cells transplantation (HSCT) and chemotherapy (HT)) in intermediate and unfavorable prognostis groups was carried out. High efficiency of related HLA-identical HSCT in patients both intermediate and unfavorable prognostis groups have been shown. Autological HSCT is possible in intermediate prognosis patients with absence of HLA-identical siblings and in unfavorable prognosis patients with absence of HLA-identical unrelated donor.